Cour Pharmaceuticals Development Co., Inc.

After raising $105 million in our Series A earlier this year, we are thrilled that as part of Chicago Inno's Fire Awards, we have been recognized as one of 50 companies setting Chicago’s innovation economy ablaze. Check out the full list by Alex Zorn here: https://bit.ly/3zqNx2Y

Today, Tim Walbert, an industry veteran with over 30 years of biotech leadership experience, was appointed to our Board of Directors. As we continue to move our nanoparticles for #MyastheniaGravis and #T1D into Phase 2 studies, we are excited to leverage his expertise in leading companies through discovering, developing and commercializing novel treatments for underserved patient populations. Read more in our press release: https://bit.ly/45IAkOJ

In this Drug Target Review article, our CEO, John J. Puisis, discusses our versatile #nanoparticle platform and its potential to treat #AutoimmuneDiseases like #MyastheniaGravis and #Type1Diabetes. Read more here: https://bit.ly/3ySKjok

More than 70,000 people are diagnosed with #MyastheniaGravis in the U.S. alone, and there is currently no cure. During #MGAwarenessMonth, we stand with MG patients as we work to develop an innovative new treatment option to give patients a better tomorrow. Our candidate CNP-106 is currently in a Phase 2 #ClinicalTrial for the treatment of MG. Learn more about the trial here: https://bit.ly/4c2AgLP #MGStrong

Join us in welcoming Paul Peloso, MD, as COUR’s Chief Medical Officer. His rich background in the biopharma industry and his expertise in late-stage clinical development make him a great addition to our team as we advance into Phase 2 studies of our potential treatments for #MyastheniaGravis and #Type1Diabetes. Read more here: https://lnkd.in/gciGDizV

We’re excited to attend #IMMUNOLOGY24™ right here in Chicago! Our Director of Immunology, Dr. Joe Podojil, will present preclinical data demonstrating the potential of our antigen-specific nanoparticle technology. Learn more about our presentation here: https://lnkd.in/eQFjkKCN #AAI2024 #immunology

If you’re attending the Myasthenia Gravis Foundation of America, Inc.’s 2024 National Patient Conference in Tampa, don’t miss our booth! We look forward to discussing our #MyastheniaGravis research, including the #ClinicalTrial of our potential treatment, CNP-106. Learn more about our study here: https://lnkd.in/eiQcxG8M 

We're #hiring a new Financial Planning Analyst in Greater Chicago Area. Apply today or share this post with your network.

Later this month, our Director of Immunology, Joe Podojil, PhD, will be at the 7th Antigen-Specific Immune Tolerance Drug Development Summit in Boston. He will lead a workshop on antigen selection and immune tolerance in #AutoimmuneDiseases. Learn more here: https://lnkd.in/ezQ82Ze

In case you missed it, this Genetic Engineering & Biotechnology News article by Jonathan D. Grinstein, PhD covers the closure of our $105 million Series A and our nanoparticle approach to antigen-specific immune tolerance. Check it out here: https://brnw.ch/21wGGMJ